Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

EyePoint Pharmaceuticals Reports Topline Phase 3 LUCIA Data for DURAVYU in Wet AMD

EyePoint, Inc. announced that its second pivotal Phase 3 trial, LUCIA, failed to meet the primary endpoint of statistical non-inferiority in visual acuity for DURAVYU in patients with wet age-related macular degeneration. Despite the primary endpoint miss, the trial met key secondary targets including significant reduction in treatment burden and a favorable safety profile.

Digital retinal photography, eyeball, digital, retinal. Stock photo illustrating EyePoint's other story.
EyePoint, Inc. · Healthcare · Photo: KattanaSox / Pixabay

Key highlights

  • Primary endpoint of non-inferiority in mean change in BCVA versus aflibercept control was not achieved
  • Trial demonstrated a 38% reduction in treatment burden with a nominal p-value under 0.0001
  • Fifty-two percent of study eyes remained supplement-free through the 56-week clinical period
  • Approximately 71% of patients required zero or one supplemental injection throughout the trial
  • Existing cash reserves of $180 million are projected to fund company operations into Q4 2027

What Happened

EyePoint reported that the LUCIA trial, evaluating DURAVYU for wet age-related macular degeneration, did not meet the primary endpoint of statistical non-inferiority in visual acuity compared to the aflibercept control group. While the drug demonstrated visual improvement, it failed to match the established standard of care in the primary efficacy metric. However, DURAVYU showed success in secondary metrics, specifically in reducing treatment burden. The data indicated that 52% of treated eyes remained supplement-free through Week 56, and 71% of participants required only zero or one supplemental injection during the study period.

Significance and Pipeline Strategy

This outcome represents a significant clinical hurdle as it is the second Phase 3 failure for DURAVYU in the wet AMD indication, following results from the LUGANO trial. Consequently, the company is re-evaluating its clinical strategy for wet AMD while shifting primary focus toward its ongoing Diabetic Macular Edema program. Management indicated that the multifactorial and inflammatory nature of DME might be better suited for the therapeutic profile of DURAVYU. The company intends to complete additional analyses of the pooled Phase 3 data to determine if a viable regulatory path remains for the wet AMD indication.

Business and Financial Context

  • EyePoint utilizes proprietary Durasert E technology for sustained-release drug delivery into the eye
  • Phase 3 DME program remains on track with topline data from COMO and CAPRI trials expected in Q4 2027
  • Company maintains $180 million in cash and marketable securities to support operations into late 2027
  • Third quarter 2026 financial results are scheduled for release on November 4, 2026
  • Clinical focus remains on reducing the frequency of invasive intravitreal injections for retinal diseases
EyePoint, Inc. share price · last month
Line chart of EyePoint, Inc.'s share price over the last month, from $0.44 on 19 Oct → $0.31 on 16 Nov; our story on 19 Oct at $2.99.

Down 89.7% since our story on 19 Oct: $2.99 when we broke it → $0.31 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$0.44
20 Oct$0.41
21 Oct$0.43
22 Oct$0.43
23 Oct$0.40
26 Oct$0.37
27 Oct$0.36
28 Oct$0.38
29 Oct$0.38
30 Oct$0.35
2 Nov$0.37
3 Nov$0.40
4 Nov$0.40
5 Nov$0.36
6 Nov$0.36
9 Nov$0.36
10 Nov$0.40
11 Nov$0.36
12 Nov$0.32
13 Nov$0.31
16 Nov$0.31

Management Perspective

“We are disappointed that the LUCIA trial did not meet the primary endpoint given the promising scientific rationale of DURAVYU and its potential to improve outcomes for patients with wet AMD.”

Jay S. Duker, M.D., President and CEO of EyePoint

Management commentary

“We are disappointed that the LUCIA trial did not meet the primary endpoint given the promising scientific rationale of DURAVYU and its potential to improve outcomes for patients with wet AMD.”

Jay S. Duker, M.D., President and Chief Executive Officer
EyePoint, Inc. · financial snapshot
Share price$2.99
Market cap$258M
Revenue (annual)$31M
1-month price change-13.33%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by EyePoint, Inc. announcing topline results from its LUCIA Phase 3 clinical trial.

Read the filing ↗

Track EyePoint, Inc. live

Get the next EyePoint, Inc. SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.